

Gastrointestinal Stromal Tumor Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/GDCD8E88288CEN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: GDCD8E88288CEN

Abstracts

The 7 major gastrointestinal stromal tumor markets reached a value of US\$ 493.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 810.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The gastrointestinal stromal tumor market has been comprehensively analyzed in IMARC's new report titled "Gastrointestinal Stromal Tumor Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034".

Gastrointestinal stromal tumor refers to a rare type of neoplasm that originates in the gastrointestinal tract, particularly in the small intestine or stomach. This disease arises from specialized cells called interstitial cells of Cajal (ICC) that regulate the movement of food through the digestive system. The symptoms of the ailment can vary based on the size and area of the tumor. Individuals suffering from this illness may experience abdominal pain or discomfort, gastrointestinal bleeding, blood in the stool, nausea, bloating, vomiting, loss of appetite, a palpable mass or swelling, feeling of fullness or early satiety, unintentional weight loss, etc. The diagnosis of the ailment typically involves a combination of medical history evaluation, physical examination, and tissue sampling. Immunohistochemistry and genetic testing can also be performed to detect specific markers and mutations associated with this condition. Furthermore, several imaging studies, such as positron emission tomography (PET) scans, magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), etc., are utilized to determine if the tumor has spread to other parts of the body.

The increasing prevalence of genetic mutations, causing uncontrolled growth and division of the ICC, which lead to the formation of tumors, is primarily driving the gastrointestinal stromal tumor market. In addition to this, the widespread utilization of

radiofrequency ablation technique, a minimally invasive procedure that uses heat generated by high-frequency radio waves to destroy cancerous cells, is also creating a positive outlook for the market. Moreover, the emerging popularity of proton pump inhibitors, including omeprazole and pantoprazole, to reduce the production of stomach acid, alleviate heartburn, and manage gastrointestinal symptoms associated with the illness is further bolstering the market growth. Apart from this, the escalating adoption of embolization therapy, since it aims to block the blood supply to the tumors, thereby making them deprived of oxygen and nutrients, is acting as another significant growth-inducing factor. Furthermore, the inflating application of targeted therapies, like imatinib, sunitinib, regorafenib, etc., to treat advanced or metastatic disease conditions by inhibiting the activity of abnormal proteins produced by the genetic mutations is expected to drive the gastrointestinal stromal tumor market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the gastrointestinal stromal tumor market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gastrointestinal stromal tumor and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gastrointestinal stromal tumor market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the gastrointestinal stromal tumor market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the gastrointestinal stromal tumor market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current gastrointestinal stromal tumor marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the gastrointestinal stromal tumor market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the gastrointestinal stromal tumor market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the gastrointestinal stromal tumor market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of gastrointestinal stromal tumor across the seven major markets?

What is the number of prevalent cases (2018-2034) of gastrointestinal stromal tumor by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of gastrointestinal stromal tumor by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with gastrointestinal stromal tumor across the seven major markets?

What is the size of the gastrointestinal stromal tumor patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of gastrointestinal stromal tumor?

What will be the growth rate of patients across the seven major markets?

Gastrointestinal Stromal Tumor: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for gastrointestinal stromal tumor drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gastrointestinal stromal tumor market?

What are the key regulatory events related to the gastrointestinal stromal tumor market?

What is the structure of clinical trial landscape by status related to the gastrointestinal stromal tumor market?

What is the structure of clinical trial landscape by phase related to the gastrointestinal stromal tumor market?

What is the structure of clinical trial landscape by route of administration related to the gastrointestinal stromal tumor market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 GASTROINTESTINAL STROMAL TUMOR - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 GASTROINTESTINAL STROMAL TUMOR - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 GASTROINTESTINAL STROMAL TUMOR - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 GASTROINTESTINAL STROMAL TUMOR - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 GASTROINTESTINAL STROMAL TUMOR - UNMET NEEDS

10 GASTROINTESTINAL STROMAL TUMOR - KEY ENDPOINTS OF TREATMENT

11 GASTROINTESTINAL STROMAL TUMOR - MARKETED PRODUCTS

- 11.1 List of Gastrointestinal Stromal Tumor Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Qinlock (Ripretinib) - Deciphera Pharmaceuticals
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Stivarga (Regorafenib) - Bayer Healthcare

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Ayyakit (Avapritinib) - Blueprint Medicines
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Sutent (Sunitinib) - Pfizer
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Gleevec (Imatinib) - Novartis
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 GASTROINTESTINAL STROMAL TUMOR - PIPELINE DRUGS

- 12.1 List of Gastrointestinal Stromal Tumor Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 PLX9486 - Cogent Biosciences
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 DS-6157a - Daiichi Sankyo
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results

- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 IDRX 42 - IDRx, Inc.
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 THE630 - Theseus Pharmaceuticals
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 Crenolanib besylate - AROG Pharmaceuticals/Pfizer
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. GASTROINTESTINAL STROMAL TUMOR - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. GASTROINTESTINAL STROMAL TUMOR – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 GASTROINTESTINAL STROMAL TUMOR - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Gastrointestinal Stromal Tumor - Market Size
 - 15.2.1.1 Market Size (2018-2023)

- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Gastrointestinal Stromal Tumor - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Gastrointestinal Stromal Tumor - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Gastrointestinal Stromal Tumor - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Gastrointestinal Stromal Tumor - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Gastrointestinal Stromal Tumor - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Gastrointestinal Stromal Tumor - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Gastrointestinal Stromal Tumor - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Gastrointestinal Stromal Tumor - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Gastrointestinal Stromal Tumor - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Gastrointestinal Stromal Tumor - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Gastrointestinal Stromal Tumor - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Gastrointestinal Stromal Tumor - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Gastrointestinal Stromal Tumor - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Gastrointestinal Stromal Tumor - Market Size
 - 15.7.1.1 Market Size (2018-2023)

- 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Gastrointestinal Stromal Tumor - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Gastrointestinal Stromal Tumor - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Gastrointestinal Stromal Tumor - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Gastrointestinal Stromal Tumor - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Gastrointestinal Stromal Tumor - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Gastrointestinal Stromal Tumor - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Gastrointestinal Stromal Tumor - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Gastrointestinal Stromal Tumor - Access and Reimbursement Overview

16 GASTROINTESTINAL STROMAL TUMOR - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 GASTROINTESTINAL STROMAL TUMOR MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 GASTROINTESTINAL STROMAL TUMOR MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Gastrointestinal Stromal Tumor Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/GDCD8E88288CEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDCD8E88288CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

